Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors

Trial Profile

A Phase 1 Study of NLG802 for Adult Patients With Recurrent Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs NLG 802 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 09 Nov 2018 Results presented in the NewLink Genetics Corporation media release.
    • 09 Nov 2018 According to a NewLink Genetics Corporation media release, results form this trial are being presented today and tomorrow at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington D.C.
    • 06 Nov 2018 According to a NewLink Genetics Corporation media release, abstracts relating to results from this trial have been published and are now available on the Society for Immunotherapy of Cancer (SITC) Conference 2018 website.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top